tiprankstipranks
Trending News
More News >
Relmada Therapeutics (RLMD)
NASDAQ:RLMD

Relmada Therapeutics (RLMD) Stock Statistics & Valuation Metrics

Compare
349 Followers

Total Valuation

Relmada Therapeutics has a market cap or net worth of $26.29M. The enterprise value is $26.28M.
Market Cap$26.29M
Enterprise Value$26.28M

Share Statistics

Relmada Therapeutics has 33,191,624 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding33,191,624
Owned by Insiders2.18%
Owned by Institutions2.20%

Financial Efficiency

Relmada Therapeutics’s return on equity (ROE) is -2.25 and return on invested capital (ROIC) is -236.14%.
Return on Equity (ROE)-2.25
Return on Assets (ROA)-1.75
Return on Invested Capital (ROIC)-236.14%
Return on Capital Employed (ROCE)-2.36
Revenue Per Employee0.00
Profits Per Employee-4.70M
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Relmada Therapeutics is -0.20. Relmada Therapeutics’s PEG ratio is -0.06.
PE Ratio-0.20
PS Ratio0.00
PB Ratio1.12
Price to Fair Value0.44
Price to FCF-0.48
Price to Operating Cash Flow-0.44
PEG Ratio-0.06

Income Statement

In the last 12 months, Relmada Therapeutics had revenue of 0.00 and earned -79.98M in profits. Earnings per share was -2.65.
Revenue0.00
Gross Profit0.00
Operating Income-83.89M
Pretax Income-79.98M
Net Income-79.98M
EBITDA-79.98M
Earnings Per Share (EPS)-2.65

Cash Flow

In the last 12 months, operating cash flow was -56.79M and capital expenditures 0.00, giving a free cash flow of -56.79M billion.
Operating Cash Flow-56.79M
Free Cash Flow-56.79M
Free Cash Flow per Share-1.71

Dividends & Yields

Relmada Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta2.09
52-Week Price Change-74.59%
50-Day Moving Average0.48
200-Day Moving Average1.39
Relative Strength Index (RSI)64.27
Average Volume (3m)996.15K

Important Dates

Relmada Therapeutics upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date

Financial Position

Relmada Therapeutics as a current ratio of 4.45, with Debt / Equity ratio of 0.00%
Current Ratio4.45
Quick Ratio4.45
Debt to Market Cap0.00
Net Debt to EBITDA0.05
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Relmada Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Relmada Therapeutics EV to EBITDA ratio is -0.15, with an EV/FCF ratio of -0.23.
EV to Sales0.00
EV to EBITDA-0.15
EV to Free Cash Flow-0.23
EV to Operating Cash Flow-0.23

Balance Sheet

Relmada Therapeutics has $27.06M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$27.06M billion.
Cash & Marketable Securities$27.06M
Total Debt$0.00
Net Cash-$27.06M
Net Cash Per Share-$0.82
Tangible Book Value Per Share$1.18

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Relmada Therapeutics is $1.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$1.00
Price Target Upside26.58% Upside
Analyst ConsensusHold
Analyst Count2
Revenue Growth Forecast
EPS Growth Forecast19.21%

Scores

Smart ScoreN/A
AI Score41.42
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis